Author:
Böll Boris,Subklewe Marion,von Bergwelt-Baildon Michael
Publisher
Springer Science and Business Media LLC
Subject
Critical Care and Intensive Care Medicine
Reference14 articles.
1. Holzinger A, Abken H (2019) CAR T Cells: a snapshot on the growing options to design a CAR. Hemasphere 3(1):e172. https://doi.org/10.1097/HS9.0000000000000172
2. Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A et al (2018) Long-term safety and efficacy of axicabtagene ciloleucel (anti-CD19 CAR T) in refractory large B-cell lymphoma: a multicenter, single arm, phase 1-2 trial. Lancet Oncol 2045(18):31–42
3. Schuster SJ, Bishop MR, Tam CS et al (2019) Long-term follow-up of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma: updated analysis of juliet study. Biol Blood Marrow Transpl 25:S20–S21
4. Crump M, Neelapu SS, Farooq U et al (2017) Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130(16):1800–1808
5. Maurer MJ, Habermann TM, Shi Q et al (2018) Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials. Ann Oncol 29(8):1822–1827
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献